denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: Checkpoint Blockade: Defining A New Treatment Paradigm in Hodgkin Lymphoma and Allogeneic Transplantation
Hematology Disease Topics & Pathways:
Biological, Therapies, checkpoint inhibitors, Adverse Events, Clinically relevant
Disclosures: Perales: Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cidara Therapeutics: Other; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria; Miltenyi Biotec: Research Funding; Incyte Corporation: Honoraria, Research Funding; Kite/Gilead: Honoraria, Research Funding; MolMed: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees, Other; NexImmune: Membership on an entity's Board of Directors or advisory committees; Medigene: Membership on an entity's Board of Directors or advisory committees, Other; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees.
OffLabel Disclosure:
See more of: Spotlight Sessions